Karolynn Halpert, MD, is a physician, healthcare executive, and translational medicine leader dedicated to advancing the responsible integration of regenerative medicine into clinical practice. She serves as Chief Medical Officer of BioXcellerator, BioXtech, and BioXscience, where she leads the clinical, scientific, and research strategy of a vertically integrated regenerative medicine ecosystem.

Dr. Halpert’s work focuses on the clinical application of Wharton’s Jelly–derived mesenchymal stromal cells, extracellular vesicles, secretome-based therapies, and advanced biologic protocols for musculoskeletal, neurologic, autoimmune, inflammatory, and degenerative conditions. Her medical leadership bridges patient care, cellular therapy manufacturing, real-world evidence generation, clinical protocol design, and scientific education.

At BioXcellerator, she has helped build one of the most comprehensive clinical follow-up and outcomes programs in the field of regenerative medicine, with a strong emphasis on safety, functional improvement, validated clinical scales, and longitudinal patient-reported outcomes. Her work is centered on moving regenerative medicine beyond anecdotal experience and toward a more structured, evidence-informed, data-driven model.

Dr. Halpert has been actively involved in the development and analysis of real-world clinical evidence evaluating the use of allogeneic Wharton’s Jelly mesenchymal stromal cells in orthopedic and sports medicine conditions, including osteoarthritis, degenerative disc disease, shoulder injuries, tendinopathies, and overuse syndromes.

In addition to her clinical and executive roles, Dr. Halpert is deeply committed to ethical medical education. She frequently speaks on the importance of scientific rigor, responsible patient communication, biologic quality, clinical transparency, and the need to distinguish serious regenerative medicine from unsupported or commercially exaggerated claims. Her mission is to help shape a future in which regenerative medicine is practiced with integrity, measurable outcomes, and respect for both science and the patient experience.

Dr. Halpert holds a medical degree, a master’s degree in health administration, and postgraduate training in Emergency Medicine and Health Services Management. Her multidisciplinary background allows her to integrate clinical judgment, systems thinking, regulatory awareness, operational leadership, and translational research into the development of next-generation regenerative medicine programs.

Through her work, Dr. Halpert continues to advocate for a model of medicine that is both innovative and responsible: one that honors the complexity of human biology, uses data to guide clinical decisions, and seeks not only to treat disease, but to restore function, resilience, and quality of life.